Emmaus Life Sciences(EMMA)
$0.02+0.01 (+53.33%)
EMMA
Emmaus Life Sciences financials statements
$0.02
At close:+0.01 (+53.33%)
Want to see EMMA full AI Analyst Report?
Emmaus Life Sciences (EMMA) Ratios
89 Followers
Emmaus Life Sciences Ratios
EMMA's free cash flow for Q2 2026 was $1.69M. For the 2026 fiscal year, EMMA's free cash flow was decreased by $-2.00K and operating cash flow was $1.69M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Jun 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.11 | 0.11 | 0.19 | 0.12 | 0.25 |
| Quick Ratio | 0.09 | 0.08 | 0.16 | 0.07 | 0.13 |
| Cash Ratio | 0.03 | 0.02 | 0.04 | 0.04 | 0.06 |
| Solvency Ratio | -0.09 | -0.08 | -0.04 | -0.13 | -0.20 |
| Operating Cash Flow Ratio | -0.00 | -0.04 | -0.02 | -0.09 | -0.03 |
| Short-Term Operating Cash Flow Coverage | -0.00 | -0.08 | -0.05 | -0.21 | -0.06 |
| Net Current Asset Value | $ -77.30M | $ -73.31M | $ -71.43M | $ -76.03M | $ -69.09M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.52 | 1.40 | 0.93 | 0.64 | 0.53 |
| Debt-to-Equity Ratio | -0.51 | -0.58 | -0.68 | -0.90 | -1.39 |
| Debt-to-Capital Ratio | -1.05 | -1.40 | -2.16 | -9.42 | 3.53 |
| Long-Term Debt-to-Capital Ratio | -0.04 | -0.04 | -0.05 | -0.12 | -0.28 |
| Financial Leverage Ratio | -0.34 | -0.42 | -0.74 | -1.41 | -2.64 |
| Debt Service Coverage Ratio | -0.01 | -0.03 | 0.10 | -0.19 | -0.51 |
| Interest Coverage Ratio | 0.03 | -0.34 | 0.48 | -1.31 | -1.98 |
| Debt to Market Cap | 37.00 | 55.30 | 5.63 | 2.14 | 0.32 |
| Interest Debt Per Share | 0.62 | 0.61 | 0.75 | 0.72 | 0.67 |
| Net Debt to EBITDA | -98.17 | -34.70 | 8.31 | -5.24 | -2.17 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.12% | 92.79% | 95.47% | 85.93% | 83.93% |
| EBIT Margin | -2.80% | -5.60% | 12.13% | -30.19% | -62.20% |
| EBITDA Margin | -2.49% | -5.46% | 12.24% | -29.90% | -61.92% |
| Operating Profit Margin | 1.85% | -11.37% | 11.96% | -35.81% | -29.73% |
| Pretax Profit Margin | -60.09% | -38.58% | -12.81% | -57.45% | -77.25% |
| Net Profit Margin | -60.16% | -38.75% | -12.61% | -57.78% | -77.37% |
| Continuous Operations Profit Margin | -60.16% | -38.75% | -12.61% | -57.78% | -77.37% |
| Net Income Per EBT | 100.12% | 100.45% | 98.44% | 100.57% | 100.16% |
| EBT Per EBIT | -3239.39% | 339.18% | -107.12% | 160.42% | 259.81% |
| Return on Assets (ROA) | -34.95% | -27.34% | -10.61% | -22.03% | -28.11% |
| Return on Equity (ROE) | 11.78% | 11.43% | 7.82% | 31.17% | 74.34% |
| Return on Capital Employed (ROCE) | -0.48% | 4.74% | -13.45% | 108.00% | -31.21% |
| Return on Invested Capital (ROIC) | -1.23% | 18.84% | 154.41% | -35.71% | -14.46% |
| Return on Tangible Assets | -34.95% | -27.34% | -10.61% | -22.03% | -28.11% |
| Earnings Yield | -899.94% | -1200.56% | -70.24% | -82.56% | -19.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.44 | 6.35 | 5.36 | 49.04 | 19.82 |
| Payables Turnover | 0.21 | 0.36 | 1.04 | 8.60 | 12.64 |
| Inventory Turnover | 0.55 | 0.73 | 0.78 | 1.09 | 0.75 |
| Fixed Asset Turnover | 14.17 | 10.57 | 12.35 | 6.40 | 5.67 |
| Asset Turnover | 0.58 | 0.71 | 0.84 | 0.38 | 0.36 |
| Working Capital Turnover Ratio | -0.21 | -0.31 | -0.60 | -0.48 | -1.03 |
| Cash Conversion Cycle | -973.63 | -450.04 | 182.08 | 300.51 | 473.57 |
| Days of Sales Outstanding | 82.19 | 57.49 | 68.12 | 7.44 | 18.42 |
| Days of Inventory Outstanding | 662.28 | 496.90 | 465.36 | 335.52 | 484.02 |
| Days of Payables Outstanding | 1718.10 | 1004.43 | 351.40 | 42.45 | 28.87 |
| Operating Cycle | 744.47 | 554.39 | 533.49 | 342.97 | 502.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.04 | -0.03 | -0.10 | -0.03 |
| Free Cash Flow Per Share | -0.00 | -0.04 | -0.03 | -0.10 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | -11.00 | -190.50 | -88.41 | -195.12 | -17.18 |
| Capital Expenditure Coverage Ratio | -11.00 | -190.50 | -88.41 | -195.12 | -17.18 |
| Operating Cash Flow Coverage Ratio | -0.00 | -0.07 | -0.05 | -0.16 | -0.04 |
| Operating Cash Flow to Sales Ratio | -0.00 | -0.14 | -0.05 | -0.28 | -0.06 |
| Free Cash Flow Yield | -1.44% | -427.54% | -28.60% | -39.62% | -1.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.11 | -0.09 | -1.42 | -1.21 | -5.16 |
| Price-to-Sales (P/S) Ratio | 0.07 | 0.03 | 0.18 | 0.70 | 3.99 |
| Price-to-Book (P/B) Ratio | -0.01 | -0.01 | -0.11 | -0.38 | -3.83 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -69.38 | -0.23 | -3.50 | -2.52 | -61.98 |
| Price-to-Operating Cash Flow Ratio | -75.68 | -0.24 | -3.54 | -2.54 | -65.59 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | -0.00 | 0.02 | 0.04 | 0.00 |
| Enterprise Value Multiple | -100.85 | -35.29 | 9.78 | -7.58 | -8.61 |
| Enterprise Value | 31.26M | 32.11M | 35.42M | 41.67M | 109.89M |
| EV to EBITDA | -100.85 | -35.29 | 9.78 | -7.58 | -8.61 |
| EV to Sales | 2.51 | 1.93 | 1.20 | 2.27 | 5.33 |
| EV to Free Cash Flow | -2605.38 | -13.97 | -23.30 | -8.17 | -82.81 |
| EV to Operating Cash Flow | -2842.23 | -14.05 | -23.56 | -8.21 | -87.63 |
| Tangible Book Value Per Share | -0.99 | -0.89 | -0.90 | -0.69 | -0.44 |
| Shareholders’ Equity Per Share | -0.99 | -0.89 | -0.90 | -0.69 | -0.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.02 | -0.01 | -0.00 |
| Revenue Per Share | 0.19 | 0.26 | 0.56 | 0.37 | 0.42 |
| Net Income Per Share | -0.12 | -0.10 | -0.07 | -0.21 | -0.32 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 1.01 | 1.00 |
| Interest Burden | 21.44 | 6.89 | -1.06 | 1.90 | 1.24 |
| Research & Development to Revenue | 0.03 | 0.04 | 0.04 | 0.09 | 0.20 |
| SG&A to Revenue | 0.89 | 1.00 | 0.50 | 0.72 | 0.65 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.04 | 0.00 | 0.03 |
| Income Quality | 0.00 | 0.35 | 0.40 | 0.48 | 0.08 |
Currency in USD

